BD Falcon TufRol Cell Culture Flask, 25 cm2 from BD Biosciences - Discovery Labware
Mouse Anti-HLA, Class II Antigen-DR+DP Monoclonal Antibody, Unconjugated, Clone 236-14240 from Meridian Life Science, Inc.
BD Falcon Cell Culture Flask, 25 cm2 from BD Biosciences - Discovery Labware
...tyrene with frosted labeling surfaces, volume grad...ting. 100% integrity tested. Linkage: This CLS num...ch Cornings product number. If showing no availabi... number (C0177) or contact customer service for as...
Biology Products:BD Falcon TufRol Cell Culture Flask, 25 cm2 from BD Biosciences - Discovery LabwareMouse Anti-HLA, Class II Antigen-DR+DP Monoclonal Antibody, Unconjugated, Clone 236-14240 from Meridian Life Science, Inc.BD Falcon Cell Culture Flask, 25 cm2 from BD Biosciences - Discovery LabwareCOSTAR FLASK 25CM2, ANGLED NECK, PHENOLIC-STYLE CAP, PS, STERILE,CS=500 from Sigma-Aldrich ...quirrels are immune to squirrelpox viral disease, ...f the species, scientists have discovered. , Sci...SL) have identified eight cases in which free-livi...squirrelpox virus by mounting an immune response. ...ournal Ecohealth . , Dr. Anthony Sainsbury, ZS...
...6, 2008) NARSAD, the world,s leading charity dedi...nual prizes tomorrow -- among the most coveted in ...ntists whose research in the areas of schizophren...orders and cognitive neuroscience have led to sign... of mental illness. , The prizes will be presen...
...essor of molecular biology at Rockefeller Universi...tical physics at New York University and at CERN i...er von Humboldt professorships ever to be awarded....ted the two scientists for this distinction, and b...ndation panel. This distinction, which comes with ...
Other Biology News:New hope for the red squirrel 2NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders 2NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders 3NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders 4NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders 5NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders 6NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders 7NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders 82 Alexander von Humboldt professorships go to LMU Munich 22 Alexander von Humboldt professorships go to LMU Munich 32 Alexander von Humboldt professorships go to LMU Munich 42 Alexander von Humboldt professorships go to LMU Munich 5(Date:12/3/2009)DALLAS, Dec. 3 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a deb
(Date:12/3/2009)HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 softwa
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Carbondioxide Incubators - A Global Market Perspective ,, http://www.reportlinker.co
(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering
Breaking Biology Technology:Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4